agilon health, inc. · 3.1/10 — Weak · Updated August 2026
Last updated: August 2026
Factor Snapshot
Invetso Quality Score
🔴 3.1 (Weak)
Core Drivers
No durable economic moat is evident: The business shows little evidence of pricing power, switching costs, or network effects, so its competitive position does not support durable excess returns.
Capital is being destroyed rather than compounded: Returns on capital and equity are deeply negative, and ongoing cash burn indicates that current operations are not converting scale into economic value.
Balance sheet risk is contained, but not enough to offset operating weakness: Leverage and liquidity are manageable, which reduces immediate financial stress, yet that protection is outweighed by persistent losses and weak cash generation.
Any upside depends on a turnaround, not on current quality: The low sales multiple and high asset turnover provide some recovery potential, but the investment case remains dependent on meaningful operational normalization.
Key Constraints
Persistent negative profitability and cash flow: Negative margins, negative free cash flow, and weak interest coverage create a fragile operating profile with limited room for error.
Weak peer-relative positioning: Relative to global peers, the company lags on profitability, capital efficiency, and moat quality, which keeps its overall investment profile below average.
Turnaround dependence raises downside asymmetry: The current setup offers limited evidence that scale is translating into durable earnings power, so the path to improved quality is uncertain and execution-sensitive.
Synthesis
AGL’s overall investment quality is weak because the decisive long-term drivers are not in place: there is no clear moat, capital efficiency is deeply negative, and cash generation remains poor. The business does have some stabilizing features, including manageable leverage and acceptable liquidity, which reduce the risk of immediate balance-sheet stress. However, those strengths are secondary to the more important issue that the company is not currently converting revenue scale into durable economic returns. Relative to global peers, it sits below average on the factors that matter most for compounding value over time. The low sales multiple and high asset turnover create turnaround optionality, but that upside depends on a meaningful and sustained improvement in margins and cash flow. Until that happens, the profile remains one of operational fragility with limited evidence of durable investment quality.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on agilon health, inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

